[Combination therapy with biguanides].
Sakura
Hiroshi
H
Diabetes Center, Tokyo Women's Medical University.
D020909:Acarbose / Q000627:therapeutic use; D001645:Biguanides / Q000627:therapeutic use*; D002839:Chromans / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D065089:Glycoside Hydrolase Inhibitors; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D008687:Metformin / Q000627:therapeutic use; D013453:Sulfonylurea Compounds / Q000627:therapeutic use; D013844:Thiazoles / Q000627:therapeutic use; D045162:Thiazolidinediones; D016896:Treatment Outcome; D000077288:Troglitazone
D001645:Biguanides; D002839:Chromans; D065089:Glycoside Hydrolase Inhibitors; D007004:Hypoglycemic Agents; D013453:Sulfonylurea Compounds; D013844:Thiazoles; D045162:Thiazolidinediones; D008687:Metformin; C089946:2,4-thiazolidinedione; D000077288:Troglitazone; D020909:Acarbose